A Randomized Phase II/III Trial Evaluating the Efficacy and Safety of 100 and 125 µg of Calcifediol Weekly Treatment of Severe Vitamin D Deficiency.

Nutrients · 2025 · PMC11857939 · PMID 40005002

Europe PMC DOI

hedged sentence

0.0200

closest p · 0.4× alpha

0.0200

boldest claim

The sentences

slightly significantp < 0.02actually significant

Starting from week 4, statistically significant differences in 25(OH)D levels were observed in both calcifediol groups compared to the placebo ( p < 0.0001) at all assessments, with slightly significant differences ( p < 0.02) between the levels of the two calcifediol groups.

also in 1,756 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.